Your trusted destination for CME, CPD & Medical Education across the Middle East.
University of Milan, Milan, Italy
Prof. Giancarlo Pruneri is an internationally recognized Italian pathologist, academic, and cancer researcher whose work has made significant contributions to diagnostic pathology, molecular oncology, and precision medicine. He is particularly known for his research in breast cancer, hematological malignancies, molecular diagnostics, and the development of advanced pathological techniques to support personalized cancer treatment.
He obtained his medical degree from the University of Milan in 1992 and completed his specialization in Pathology at the same university in 1996. Following his specialist training, he pursued academic and research appointments at the University of Milan and the European Institute of Oncology (IEO) in Milan, where he developed extensive experience in diagnostic pathology, translational cancer research, and molecular characterization of tumors.
During his career at the European Institute of Oncology, Prof. Pruneri progressed through several academic and clinical leadership positions, including Assistant Professor and Vice-Director of the Division of Pathology. His work involved the pathological assessment of breast cancer, lymphoma, leukemia, and other malignancies. He also contributed to the development of improved sentinel lymph node examination techniques, helping strengthen the accuracy of breast cancer diagnosis and surgical decision-making.
In 2015, he became Associate Professor of Pathology at the University of Milan and subsequently assumed leadership responsibilities at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan. He has served as Director of the Department of Diagnostic Pathology and Laboratory Medicine and currently leads Pathological Anatomy 2 and the Department of Services and Advanced Diagnostics.
Prof. Pruneri's research focuses on understanding the molecular and pathological characteristics of cancer, identifying biomarkers associated with treatment response, and improving diagnostic approaches for precision oncology. His scientific contributions include research on breast cancer, tumor-infiltrating lymphocytes, endocrine resistance, molecular alterations in hematological malignancies, and the clinical application of genomic testing.
Beyond his institutional responsibilities, he has held several prominent positions in international scientific organizations. He has chaired the Translational Research Working Group of the International Breast Cancer Study Group and contributed to international clinical trials, including BIG 1-98, ALTTO, and MINDACT. He has also served as Editor-in-Chief of Tumori Journal and Specialty Editor of The Breast, supporting the dissemination of scientific research and advances in cancer diagnosis and treatment.

LUMINA
LUMINA